The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH ...

Medications like Ozempic mimic a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which helps regulate blood sugar and appetite. GLP-1 is primarily secreted from the intestines, ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

PureHealth Research today announced the launch of its new line of vein health supplements, offering a natural approach to supporting healthy circulation and promoting the appearance of ...

They improve insulin sensitivity, reduce hunger signals and help people feel fuller for longer. They don’t magically repair ...

If you have MASH, GLP-1 medications may help treat the condition. Set yourself up for success with expert advice on diet, exercise, dose scheduling, and more.